Johnson & Johnson (JNJ) Buy, Sell or Hold

Johnson & Johnson (JNJ)

257.78

-1.58 (0.61%)

as of Oct 21, 2026, 8:00:00 pm Market Closed.

697 watching

BUY ON WEAKNESS

Analysts have target around the $72 area. Current PE is around 16. Earnings are coming out tomorrow, so hold off until these are released. Doesn't like to play them after they've had their first bounce.

BUY

Has under performed since its high in October. Pharmaceutical industry is facing a lot of issues. Trades around 12 X earnings with a yield of about 2.3%. Very well run company. Expecting very good earnings growth. Throws up a lot of free cash flow.

DON'T BUY

Has done better than the other US pharmaceuticals. The sector has not done well. This will be a tough hold because generics will give a lot of competition.

BUY

One of the best consumer product companies with a big medical exposure. Recent study indicated stents are no more effective than drugs, so the stock dropped. A great hedge against a weaker US economy.

TOP PICK

Feels you can get a double-digit return out of this one. Good opportunities for earnings improvement. Good price.

BUY

He likes it for the health care products, more than for the pharmaceutical and medical devices. The stent business is under serious question right now. Trades at a very reasonable PE.

DON'T BUY

Looking a lot better than it did, but still overvalued. His model price is $56.90. Negative 8% differential.

BUY

Likes this a lot. A multinational which pays a dividend.

BUY

A great company and well run. While diversified with pharmaceuticals and consumer products. Throws off lots of free cash flow.

HOLD

This is a company that will have lower return, but more stable. There is a good opportunity for a return in the future.

DON'T BUY

Model price of $57.07, a negative 14% differential. Typical of consumer staples where the market rotated into heavily this year.

BUY

Household products form a base for this company, and he sees the pharmaceuticals as an add-on. Excellent earnings.

BUY

Looks interesting. More consumer products than some of the other large pharmas.

DON'T BUY

His model price is $53.22 which is a negative 17% differential. If you want a great company in your portfolio for 20/30 years, this may be the one, or if you're trying to beat the S&P 500.

BUY

All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.

Showing 541 to 555 of 630 entries

Most Recent Experts

Gordon Reid

GoodReid Investment Counsel

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)